- 2 - 
OF RESEARCH AND DEVELOPMENT. It IS FOR THIS REASON THAT WE ARE 
PLEASED TO APPEAR BEFORE YOUR SUBCOMMITTEE AND OFFER COMMENTS IN 
SUPPORT OF A DEVELOPING PUBLIC POLICY THAT HOPEFULLY WILL MAXIMIZE 
BENEFITS AND MINIMIZE RISKS, 
We have ATTEMPTED., IN PREPARING FOR THE HEARINGS, TO ASSESS 
THE EXTENT OF THE ACTIVITY OF OUR MEMBER FIRMS IN THIS PIONEERING AREA. 
The RESPONSES REVEALED THAT ALL OF THE MAJOR RESEARCH-ORIENTED 
PHARMACEUTICAL FIRMS (ABOUT 30 ) ARE VERY MUCH INTERESTED IN IT BUT 
THAT ONLY A FEW ARE NOW ACTIVELY ENGAGED IN RECOMBINANT DNA RESEARCH. 
IT ALSO APPEARS THAT SOME OF THESE FIRMS ARE INVOLVED IN SUCH 
RESEARCH AS MANUFACTURERS OF OTHER THAN MEDICINAL CHEMICALS. 
WE DO NOT KNOW THE EXTENT OF THEIR EFFORTS IN THESE OTHER FIELDS AND 
WE MUST, THEREFORE, LIMIT OUR COMMENTS TO THEIR ACTIVITIES IN BIO- 
MEDICAL RESEARCH. 
IN VIEW OF THE TECHNICAL NATURE OF THIS SUBJECT, I WOULD LIKE TO 
have Dr. Adams present the remainder of our statement and for him 
AND Dr. UdENFRIEND TO ANSWER YOUR QUESTIONS. I AM SURE IT WILL BE 
CLEAR FROM Dr. ADAMS' STATEMENT THAT THE DRUG INDUSTRY ENDORSES THE 
SPIRIT AND INTENT OF THE GUIDELINES RECENTLY PROPOSED BY THE NATIONAL 
Institutes of Health. With some minor modifications, which Dr. Adams 
WILL IDENTIFY, IT IS OUR OPINION THAT THE DRUG INDUSTRY SHOULD AND 
WILL ACCEPT THE GUIDELINES AS AN AFFIRMATIVE AND CONSTRUCTIVE APPROACH, 
SlAJlMENl-BY PR., J.QHN-Ga-A^AMS 
Mr. Chairman: 
As YOU AND THE MEMBERS OF THE SUBCOMMITTEE KNOW, THE PRESCRIPTION 
PHARMACEUTICAL INDUSTRY IS VERY HEAVILY INVOLVED IN GENERAL AND 
BIOMEDICAL RESEARCH, OUR MEMBER FIRMS HAVE DEMONSTRATED A HIGH 
[ 110 ] 
